1. Pink Sheet
  2. >>Market Access
  4. >>Medicare

Medicare Premiums and Aduhelm: The Political Headache Continues

 
• By Nielsen Hobbs

CMS took pains in its final national coverage determination to try to mend fences with FDA; how the NCD will play with Medicare recipients remains an open question, especially since the Alzheimer’s-induced premium hikes remain in effect.

brain puzzle
CMS HAS YET TO PUZZLE OUT HOW TO LOWER MEDICARE PREMIUMS EVEN AFTER BIOGEN CUT ADUHELM’S PRICE AND MEDICARE OPTED NOT TO COVER THE PRODUCT OUTSIDE OF TRIALS. • Source: Getty

The Centers for Medicare and Medicaid Services’ national coverage determination for Alzheimer’s drugs leaves drug sponsors with a longer road to reimbursement, but also leaves a fair bit of unfinished for the agency itself.

The

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

More from Government Payers